Thu, April 11, 2013
[ Thu, Apr 11th 2013 ] - Market Wire
15 PM EDT
Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ] - Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013
Wed, April 3, 2013
Tue, April 2, 2013
Mon, April 1, 2013
Fri, March 29, 2013
Thu, March 28, 2013
Wed, March 27, 2013
Tue, March 26, 2013
Mon, March 25, 2013
[ Mon, Mar 25th 2013 ] - Market Wire
Health Canada Decision Appealed
Sun, March 24, 2013
Fri, March 22, 2013
Thu, March 21, 2013
Wed, March 20, 2013
[ Wed, Mar 20th 2013 ] - Market Wire
00am ET
Tue, March 19, 2013
Mon, March 18, 2013
Sun, March 17, 2013
Fri, March 15, 2013
Thu, March 14, 2013

Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference


//health-fitness.news-articles.net/content/2013/ .. -leaders-in-the-biotech-industry-conference.html
Published in Health and Fitness on Friday, March 29th 2013 at 4:16 GMT by Market Wire   Print publication without navigation


Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference -- SEATTLE, March 29, 2013 /PRNewswire/ --

SEATTLE, March 29, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: [ OMER ]), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it has been chosen to present at the 2013 Future Leaders in the Biotech Industry Conference.  Gregory A. Demopulos , M.D., chairman and chief executive officer, is scheduled to present at 9:30 a.m. Eastern Time on Friday, April 5, 2013.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at [ www.omeros.com ].  

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

SOURCE Omeros Corporation



RELATED LINKS
[ http://www.omeros.com ]

Publication Contributing Sources